Every 10-Q that NextPlat Corp (NXPL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NXPL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXPL filings page.
NextPlat Corp reported lower revenue but sharply improved profitability for the three and six months ended June 30, 2026. Quarterly revenue fell to $11.9 million from $13.2 million, and year‑to‑date revenue declined to $21.7 million from $27.2 million, driven mainly by reduced healthcare prescription volumes and reimbursement rates. e‑Commerce revenue was roughly flat.
Mix shift and new contracts significantly improved margins. Gross margin rose to 40% in the quarter and 37% year‑to‑date, versus 22% and 21% a year earlier, helped by higher‑margin 340B and medication‑fulfillment contracts and the Medicare Maximum Fair Price program. Net loss narrowed to $0.1 million for the quarter and $1.3 million year‑to‑date, from $1.8 million and $3.7 million, respectively.
The company held $11.9 million of cash and $14.2 million of working capital, and has $3.8 million of remaining capacity under an at‑the‑market equity program. Management concluded that these resources and its plans alleviate prior substantial doubt about continuing as a going concern. NextPlat also recorded a $1.75 million legal accrual related to a Delaware class action and disclosed ongoing material weaknesses in internal control, along with a $0.4 million liquidated‑damages obligation under a registration rights agreement.
NextPlat Corp reported a smaller loss but lower revenue for the quarter ended March 31, 2026. Revenue fell to $9.9 million from $13.9 million, driven by a sharp decline in healthcare prescription revenue, partly offset by modest e‑Commerce growth.
Gross margin improved to about 35% from 21%, helped by higher‑margin pharmacy contract revenue and better drug pricing, reducing net loss to $1.1 million versus $1.9 million a year earlier. Cash was $11.0 million with working capital of about $14.2 million, and the company established a new at‑the‑market equity program of up to $3.7 million. Management notes past recurring losses raised substantial doubt about continuing as a going concern but believes current plans and liquidity mitigate this. The quarter also reflects an accrued litigation reserve of $1.75 million and ongoing material weaknesses in internal controls that remain under remediation.
NextPlat Corp reported a narrower quarterly loss while revenue declined. For the three months ended September 30, 2025, revenue was $13.8 million versus $15.4 million a year ago, driven by lower Healthcare segment sales, including a drop in 340B contract revenue. Net loss was $2.2 million compared with $7.7 million last year, and basic and diluted loss per share improved to $0.08 from $0.22.
Gross profit was $2.7 million (down from $3.6 million), as e‑Commerce contributed $3.7 million and Healthcare contributed $10.1 million of revenue. Operating expenses decreased year over year without last year’s impairment and higher professional fees. Results include a $250,000 loss on settlement of litigation recognized this quarter.
Cash was $13.9 million as of September 30, 2025 (from $20.0 million at December 31, 2024), with net cash used in operating activities of $5.8 million for the nine‑month period. Total assets were $30.0 million. Under its $2.0 million share repurchase program, the company repurchased approximately $0.1 million year to date; 26,304,987 common shares were outstanding as of November 10, 2025 (excluding 130,549 held as treasury stock).